ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $35,395.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $70.79, for a total value of $35,395.00. Following the completion of the transaction, the vice president directly owned 73,924 shares of the company’s stock, valued at $5,233,079.96. This represents a 0.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $75.48, for a total value of $37,740.00.
• On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $81.84, for a total value of $40,920.00.

ANI Pharmaceuticals Price Performance

ANIP opened at $73.59 on Thursday. The stock has a fifty day simple moving average of $76.47 and a two-hundred day simple moving average of $78.11. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The company has a market cap of $1.69 billion, a price-to-earnings ratio of 15.86 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a 12-month low of $69.58 and a 12-month high of $98.55.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Ranger Investment Management L.P. purchased a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $28,406,000. Deutsche Bank AG purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth $26,775,000. William Blair Investment Management LLC purchased a new position in shares of ANI Pharmaceuticals in the second quarter worth $21,372,000. Parkman Healthcare Partners LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $16,797,000. Finally, Bank of America Corp DE bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $15,154,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ANIP. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price target on the stock. Guggenheim reduced their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Canaccord Genuity Group reduced their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $103.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.